论文部分内容阅读
目的探讨P53与错配修复基因(hMLH1)在子宫内膜癌的表达情况与其临床病理学特征以及分期之间的关系。方法采用免疫组织化学方法检测42例子宫内膜癌P53与hMLH1蛋白的表达情况。结果42例子宫内膜癌P53蛋白阳性表达率为(18/42)42·85%。病理分级1级中占(4/15)26·67%。Ⅱ~Ⅲ级中占(14/27)51·85%,比较两者有显著差异。hMLH1蛋白表达率为(7/42)16·67%,病理分级1级中占(5/15)33·33%,Ⅱ~Ⅲ级中占(2/27)7·40%,比较两者有显著差异。淋巴结阳性12例的子宫内膜癌中P53表达率(9/12)75%.hMLH1表达率为(2/12)16·67%。结论P53与子宫内膜癌的分化程度、淋巴转移有关,hMLH1与子宫内膜癌的分化程度有关、与淋巴转移无关,两者均有利于判断其预后。
Objective To investigate the relationship between the expression of P53 and hMLH1 in endometrial carcinoma and its clinical pathological features and staging. Methods Immunohistochemistry was used to detect the expression of P53 and hMLH1 protein in 42 cases of endometrial carcinoma. Results The positive rate of P53 protein in 42 cases of endometrial carcinoma was 42.85%. Pathological grade 1 accounted for (4/15) 26 · 67%. Ⅱ ~ Ⅲ grade accounted for (51/27) 51 · 85%, compared with the two significant differences. The expression rate of hMLH1 protein was (16/67) 16.67%, the pathological grade 1 grade was 33.33% (5/15), and the grade Ⅱ ~ Ⅲ was (2.27) 7.40% There are significant differences. The positive rate of P53 expression in endometrial carcinoma (9/12) of lymph node positive 12 cases was 75%, hMLH1 expression was (16/12) 16.67%. Conclusions P53 is related to the degree of differentiation and lymphatic metastasis of endometrial carcinoma, hMLH1 is related to the differentiation degree of endometrial carcinoma and has nothing to do with lymph node metastasis, both of which are helpful to judge the prognosis.